A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
A phase 2 trial of Atezolizumab, Fruquintinib in colorectal cancer, run by Kahr Bio Australia Pty Ltd, now recruiting.
Overview
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. is a phase 2 interventional study registered as NCT07235293 by Kahr Bio Australia Pty Ltd, with 90 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09-30. Interventions recorded: DSP107 + Atezolizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Shares Fruquintinib, Colorectal cancer.
- TrialA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Shares Atezolizumab, Colorectal cancer.
- TrialStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Shares Fruquintinib, Colorectal cancer.
- TrialFRESCO-2
Shares Fruquintinib, Colorectal cancer.
- TrialInjection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
Shares Fruquintinib, Colorectal cancer.
- PersonJin Li
Shares Fruquintinib, Colorectal cancer.
- TrialA Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Shares Fruquintinib, Colorectal cancer.
- TrialA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Shares Atezolizumab, Colorectal cancer.